1975
SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION
Canellos G, Arseneau J, Devita V, Whang-Peng J, Johnson R. SECOND MALIGNANCIES COMPLICATING HODGKIN'S DISEASE IN REMISSION. The Lancet 1975, 305: 947-949. PMID: 48122, DOI: 10.1016/s0140-6736(75)92007-3.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic AgentsCarcinoma, Squamous CellChromosome AberrationsColonic NeoplasmsFemaleFibrosarcomaHodgkin DiseaseHumansImmunosuppression TherapyLeukemia, Monocytic, AcuteLeukemia, Myeloid, AcuteLung NeoplasmsMaleMiddle AgedNeoplasmsNeoplasms, Radiation-InducedRadiotherapyRemission, SpontaneousSkin NeoplasmsConceptsIntensive radiotherapyCombination chemotherapyPatients treated with standard chemotherapyCourse of Hodgkin's diseaseRelapse of diseaseAcute myeloid leukemiaMan-years of follow-upMode of treatmentMechanisms of oncogenesisStandard chemotherapyHodgkin's diseaseChromosomal abnormalitiesMyeloid leukemiaImmunosuppressive effectsRadiotherapyFollow-upChemotherapyTumorHigh riskCellular effectsPatientsDiseaseIncidenceTreatmentRisk
1970
Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease
Chabner B, DeVita V, Livingston D, Oliverio V. Abnormalities of Tryptophan Metabolism and Plasma Pyridoxal Phosphate in Hodgkin's Disease. New England Journal Of Medicine 1970, 282: 838-843. PMID: 5418547, DOI: 10.1056/nejm197004092821504.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseUntreated patientsPlasma levelsPlasma pyridoxal phosphate levelsPlasma pyridoxal phosphatePyridoxal phosphate levelsAdvanced diseaseComplete remissionSymptomatic diseaseImmunosuppressive effectsAbnormal resultsPyridoxine deficiencyNormal limitsTryptophan metabolismPatientsDiseasePyridoxal phosphatePhosphate levelsDeficiencyL-tryptophanLittle evidenceMetabolismRemissionChemotherapyAnemia